BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals logo

Founded
2002
Geography
United States of America based
Funding
$1534.600 M

Alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as RNA interference, or RNAi. With RNAi technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today&s;s medicines.

R&D Platform


Pipelines

No pipelines published yet

Products

 

Services

No services posted yet